




The relative strengths and weaknesses of Moonlake Immunotherapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moonlake Immunotherapeutics compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 92% points. The greatest weakness of Moonlake Immunotherapeutics is the variable Net Income, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 315%, being 70% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	76,511
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,665
Liabilities, Non-Current	411
Other Assets	283
Other Compr. Net Income	15,069
Other Expenses	36
Other Liabilities	0
Other Net Income	592
Other Revenues	0
Property and Equipment	49
Research and Development	42,049
Selling, General and Administrative Expense	23,012

Output Variable	Value in 1000 USD
Assets	76,843
Liabilities	8,077
Expenses	65,098
Revenues	0
Stockholders Equity	68,767
Net Income	-64,506
Comprehensive Net Income	-56,972
BaseVar	82,839
ECR before LimitedLiability	219%
Economic Capital Ratio	315%